Pembrolizumab (Keytruda) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Pembrolizumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells. Anti-Pembrolizumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Pembrolizumab.
Klonalität:
Polyclonal
Reinheit:
Antigen affinity chromatography
Formulierung:
Purified
Application Verdünnung:
ELISA detection: 0.01-0.1 ,µg/ml
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
